JP2014521089A - 液体試料中のアミロイドベータオリゴマーの検出方法およびその使用 - Google Patents

液体試料中のアミロイドベータオリゴマーの検出方法およびその使用 Download PDF

Info

Publication number
JP2014521089A
JP2014521089A JP2014520229A JP2014520229A JP2014521089A JP 2014521089 A JP2014521089 A JP 2014521089A JP 2014520229 A JP2014520229 A JP 2014520229A JP 2014520229 A JP2014520229 A JP 2014520229A JP 2014521089 A JP2014521089 A JP 2014521089A
Authority
JP
Japan
Prior art keywords
antibody
oligomer
ndpoi
oligomers
assay
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014520229A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014521089A5 (enExample
Inventor
サベージ，メアリー
シユグリユー，ポール
ウオルフ，アビガイル
マキヤンベル，アレクサンダー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp & Dohme LLC
Original Assignee
Merck Sharp & Dohme LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme LLC filed Critical Merck Sharp & Dohme LLC
Publication of JP2014521089A publication Critical patent/JP2014521089A/ja
Publication of JP2014521089A5 publication Critical patent/JP2014521089A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Neurosurgery (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Neurology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
JP2014520229A 2011-07-13 2012-07-09 液体試料中のアミロイドベータオリゴマーの検出方法およびその使用 Pending JP2014521089A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161507332P 2011-07-13 2011-07-13
US61/507,332 2011-07-13
PCT/US2012/045886 WO2013009667A1 (en) 2011-07-13 2012-07-09 Method for detection of amyloid beta oligomers in a fluid sample and uses thereof

Publications (2)

Publication Number Publication Date
JP2014521089A true JP2014521089A (ja) 2014-08-25
JP2014521089A5 JP2014521089A5 (enExample) 2015-08-27

Family

ID=47506433

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014520229A Pending JP2014521089A (ja) 2011-07-13 2012-07-09 液体試料中のアミロイドベータオリゴマーの検出方法およびその使用

Country Status (13)

Country Link
US (2) US20130052670A1 (enExample)
EP (2) EP2732286A4 (enExample)
JP (1) JP2014521089A (enExample)
KR (1) KR20140072019A (enExample)
CN (1) CN103782171B (enExample)
AU (1) AU2012282825B2 (enExample)
BR (1) BR112014000671A2 (enExample)
CA (1) CA2840976A1 (enExample)
DK (1) DK2732289T3 (enExample)
ES (1) ES2666840T3 (enExample)
MX (1) MX2014000480A (enExample)
RU (1) RU2014105172A (enExample)
WO (2) WO2013009667A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018526642A (ja) * 2015-08-25 2018-09-13 プロセナ バイオサイエンシーズ リミテッド リン酸化アルファ−シヌクレインを検出するための方法
JP2024534269A (ja) * 2021-08-30 2024-09-18 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド 神経変性疾患を治療するための方法および物質

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220084437A (ko) 2009-06-17 2022-06-21 바이오젠 엠에이 인코포레이티드 대상에게서 ｓｍｎ２ 스플라이싱을 조정하기 위한 조성물 및 방법
US9320793B2 (en) * 2010-07-14 2016-04-26 Acumen Pharmaceuticals, Inc. Method for treating a disease associated with soluble, oligomeric species of amyloid beta 1-42
EP2943225A4 (en) 2013-01-09 2016-07-13 Ionis Pharmaceuticals Inc COMPOSITIONS AND METHODS FOR MODULATING SMN2 DISTRIBUTION IN THE BODY OF A PATIENT
ES2874704T3 (es) * 2013-11-20 2021-11-05 Univ Iowa Res Found Procedimiento para monitorizar la eficacia de un tratamiento de la enfermedad de Alzheimer con una isoforma de ApoE
US20170044538A1 (en) 2014-04-17 2017-02-16 Biogen Ma Inc. Compositions and Methods for Modulation of SMN2 Splicing in a Subject
WO2015175769A1 (en) 2014-05-15 2015-11-19 Biogen Ma Inc. Methods for the detection of amyloid beta oligomers in biological samples
WO2016040748A1 (en) * 2014-09-12 2016-03-17 Ionis Pharmaceuticals, Inc. Compositions and methods for detection of smn protein in a subject and treatment of a subject
MA41480A (fr) * 2014-10-17 2017-12-19 Glenmark Pharmaceuticals Sa Anticorps qui se lient au ccr6 et leurs utilisations
CN108603880B (zh) 2016-02-08 2021-01-05 希森美康株式会社 受试物质的检测方法及受试物质的检测用试剂盒
US11198867B2 (en) 2016-06-16 2021-12-14 Ionis Pharmaceuticals, Inc. Combinations for the modulation of SMN expression
WO2021005857A1 (ja) * 2019-07-05 2021-01-14 株式会社 島津製作所 アミロイドベータに対するモノクローナル抗体、及びその抗体を用いるアミロイドベータ関連ペプチドの測定方法
AU2021225957A1 (en) 2020-02-28 2022-09-08 Ionis Pharmaceuticals, Inc. Compounds and methods for modulating SMN2
US20260202426A1 (en) * 2021-06-25 2026-07-16 Jae Won Chang Early diagnosis system utilizing standard deviation and autocorrelation of dynamic fluorescent or x-ray
EP4562427A4 (en) * 2022-07-27 2026-07-15 Durin Life Sciences Inc EARLY DETECTION AND MONITORING OF NEURODEGENERATIVE DISEASES USING A MULTI-DISEASE DIAGNOSTIC PLATFORM
CN117589996A (zh) * 2022-08-09 2024-02-23 深圳智源生物医药有限公司 强毒性淀粉样蛋白寡聚体的诊断用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110166035A1 (en) * 2009-11-24 2011-07-07 Probiodrug Ag Novel diagnostic method

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4665024A (en) 1984-10-01 1987-05-12 Becton, Dickinson And Company Fluorescent gram stain
US6218506B1 (en) 1997-02-05 2001-04-17 Northwestern University Amyloid β protein (globular assembly and uses thereof)
US6082205A (en) 1998-02-06 2000-07-04 Ohio State University System and device for determining particle characteristics
ATE283285T1 (de) 1999-08-04 2004-12-15 Univ Southern California Globularer aufbau vom amyloid-beta- protein und deren verwendungen
CN1871517A (zh) * 2002-02-19 2006-11-29 免疫公司 快速有效分离循环癌细胞的方法和试剂
US7807157B2 (en) 2004-02-20 2010-10-05 Intellect Neurosciences Inc. Monoclonal antibodies and use thereof
CA2561532A1 (en) * 2004-04-02 2005-10-20 Merck & Co., Inc. Methods for detecting substances which bind to the amyloid precursor protein or beta amyloid fragments, and binding compounds
US7572640B2 (en) 2004-09-28 2009-08-11 Singulex, Inc. Method for highly sensitive detection of single protein molecules labeled with fluorescent moieties
KR20070094890A (ko) 2004-10-25 2007-09-27 머크 앤드 캄파니 인코포레이티드 안티 ａｄｄｌ 항체 및 그 용도
US7731962B2 (en) 2005-02-14 2010-06-08 Merck & Co., Inc. Anti-ADDL monoclonal antibody and use thereof
AU2006306553B9 (en) * 2005-10-21 2011-09-29 Merck Sharp & Dohme Corp. Anti-ADDL monoclonal antibody and use thereof
US20090181359A1 (en) * 2007-10-25 2009-07-16 Lou Sheng C Method of performing ultra-sensitive immunoassays
US8795664B2 (en) * 2010-06-04 2014-08-05 Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin Monoclonal antibodies targeting amyloid beta oligomers
US20130115227A1 (en) * 2010-07-14 2013-05-09 Renee C. Gaspar Anti-addl monoclonal antibody and uses thereof
US9320793B2 (en) * 2010-07-14 2016-04-26 Acumen Pharmaceuticals, Inc. Method for treating a disease associated with soluble, oligomeric species of amyloid beta 1-42

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110166035A1 (en) * 2009-11-24 2011-07-07 Probiodrug Ag Novel diagnostic method

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018526642A (ja) * 2015-08-25 2018-09-13 プロセナ バイオサイエンシーズ リミテッド リン酸化アルファ−シヌクレインを検出するための方法
JP2021193374A (ja) * 2015-08-25 2021-12-23 プロセナ バイオサイエンシーズ リミテッド リン酸化アルファ−シヌクレインを検出するための方法
JP6989927B2 (ja) 2015-08-25 2022-02-03 プロセナ バイオサイエンシーズ リミテッド リン酸化アルファ－シヌクレインを検出するための方法
JP7244949B2 (ja) 2015-08-25 2023-03-23 プロセナ バイオサイエンシーズ リミテッド リン酸化アルファ－シヌクレインを検出するための方法
JP2024534269A (ja) * 2021-08-30 2024-09-18 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド 神経変性疾患を治療するための方法および物質

Also Published As

Publication number Publication date
WO2013009703A3 (en) 2013-03-21
AU2012282825A1 (en) 2014-01-16
EP2732289A2 (en) 2014-05-21
EP2732286A1 (en) 2014-05-21
US20140120037A1 (en) 2014-05-01
EP2732289B1 (en) 2018-04-11
MX2014000480A (es) 2014-06-23
CN103782171A (zh) 2014-05-07
KR20140072019A (ko) 2014-06-12
DK2732289T3 (en) 2018-05-22
BR112014000671A2 (pt) 2017-02-14
AU2012282825B2 (en) 2016-05-26
US20130052670A1 (en) 2013-02-28
CA2840976A1 (en) 2013-01-17
WO2013009703A8 (en) 2014-01-23
CN103782171B (zh) 2016-12-14
WO2013009667A1 (en) 2013-01-17
RU2014105172A (ru) 2015-08-20
WO2013009703A2 (en) 2013-01-17
ES2666840T3 (es) 2018-05-08
EP2732286A4 (en) 2015-02-25

Similar Documents

Publication Publication Date Title
AU2012282825B2 (en) Method for detection of amyloid beta oligomers in a fluid sample and uses thereof
JP5657382B2 (ja) 高感度イムノアッセイおよび生物学的な目的ペプチドおよびタンパク質の測定用キット
JP2015514206A (ja) 抗ベータアミロイド抗体の検出に関する方法及びキット
WO2011064225A1 (en) Novel diagnostic method for the diagnosis of alzheimer's disease or mild cgnitive impairment
JP2024001208A (ja) 認知症の診断および／または予測のためのアドレノメデュリン（ａｄｍ）、ならびに認知症の治療または予防における使用のための抗アドレノメデュリンバインダー
JP2015511014A (ja) アルツハイマー病の診断、予後および監視におけるオリゴマー型Ａβ
US9310383B2 (en) Antibodies, kit and method for detecting amyloid beta oligomers
US20250020669A1 (en) Methods for detecting neurofilament light chain in plasma and cerebrospinal fluid
JP2018501482A (ja) ｐＧｌｕ−Ａｂｅｔａペプチドの検出のための新規の方法
TWI892069B (zh) 用於偵測Tau蛋白或其片段的方法與套組
WO2026005695A1 (en) Detection of oligomeric tau and soluble tau aggregates
US20170363644A1 (en) Compositions and methods for use in diagnosis of alzheimer's disease
CN121773336A (zh) P-tau免疫测定
WO2025260029A1 (en) Method for quantifying amyloid beta protofibril
JP2014070037A (ja) アルツハイマー病の診断薬および診断方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150706

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150706

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20160520

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160524

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160823

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20161115

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20170613